ArriVent BioPharma (AVBP) Stock Price, News & Analysis

Company Overview

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Key Stats

• Today's Range: $22.55 to $25.73
• 50-Day Range: $17.90 to $25.42
• 52-Week Range: $15.47 to $36.37
• Volume: 788,766 shs
• Average Volume: 227,629 shs
• Market Capitalization: $803.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.29
• Consensus Rating: Buy

ArriVent BioPharma Stock Analysis - MarketRank™

ArriVent BioPharma scored higher than 17% of companies evaluated by MarketBeat, and ranked 853rd out of 924 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

ArriVent BioPharma has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ArriVent BioPharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for ArriVent BioPharma are expected to decrease in the coming year, from ($2.74) to ($3.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ArriVent BioPharma is -6.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ArriVent BioPharma is -6.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ArriVent BioPharma has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

29.45% of the float of ArriVent BioPharma has been sold short.

Short Interest Ratio / Days to Cover

ArriVent BioPharma has a short interest ratio ("days to cover") of 23.4, which indicates bearish sentiment.

Change versus previous month

Short interest in ArriVent BioPharma has recently increased by 3.62%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ArriVent BioPharma does not currently pay a dividend.

Dividend Growth

ArriVent BioPharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

29.45% of the float of ArriVent BioPharma has been sold short.

Short Interest Ratio / Days to Cover

ArriVent BioPharma has a short interest ratio ("days to cover") of 23.4, which indicates bearish sentiment.

Change versus previous month

Short interest in ArriVent BioPharma has recently increased by 3.62%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for ArriVent BioPharma this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.58% of the stock of ArriVent BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 9.48% of the stock of ArriVent BioPharma is held by institutions.

AVBP Stock Analysis - Frequently Asked Questions

How have AVBP shares performed this year?

ArriVent BioPharma's stock was trading at $26.64 at the start of the year. Since then, AVBP shares have decreased by 8.0% and is now trading at $24.5050.
View the best growth stocks for 2025 here.

How were ArriVent BioPharma's earnings last quarter?

ArriVent BioPharma, Inc. (NASDAQ:AVBP) posted its quarterly earnings data on Monday, May, 12th. The company reported ($1.90) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by $1.24.

When did ArriVent BioPharma IPO?

ArriVent BioPharma (AVBP) raised $175 million in an initial public offering (IPO) on Friday, January 26th 2024. The company issued 9,722,222 shares at a price of $18.00 per share.

Who are ArriVent BioPharma's major shareholders?

ArriVent BioPharma's top institutional shareholders include Infinitum Asset Management LLC (6.04%), Vanguard Group Inc. (4.42%), Charles Schwab Investment Management Inc. (0.58%) and Woodline Partners LP (0.43%). Insiders that own company stock include Hillhouse Investment Managemen and Orbimed Advisors Llc.
View institutional ownership trends.

How do I buy shares of ArriVent BioPharma?

Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ArriVent BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ArriVent BioPharma investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), Opendoor Technologies (OPEN), Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 6/23/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVBP
• Previous Symbol: NASDAQ:AVBP
• CIK: 1868279
• Web: www.arrivent.com
• Phone: 628-277-4836
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $39.29
• High Stock Price Target: $45.00
• Low Stock Price Target: $36.00
• Potential Upside/Downside: +66.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$80.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.21%
• Return on Assets: -46.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.34
• Quick Ratio: 14.34

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.65 per share
• Price / Book: 3.08

Miscellaneous

• Outstanding Shares: 34,210,000
• Free Float: 27,856,000
• Market Cap: $806.33 million
• Optionable: N/A
• Beta: 1.26